MindMaze Therapeutics Holding SA AI Stock Analysis
Want to see CH:MMTX full AI Analyst Report?
MindMaze Therapeutics Holding SA (MMTX) AI Stock Analysis
MindMaze Therapeutics Holding SA
(Six Swiss:MMTX)
The score is primarily held back by weak financial fundamentals (continued losses and negative free cash flow) and bearish technicals (below major moving averages with negative MACD). Valuation does not provide support because the company is unprofitable and no dividend yield is available.
MindMaze Therapeutics Holding SA (MMTX) vs. iShares MSCI Switzerland ETF (EWL)
- Market Cap
- CHF 24.80M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.05M
- Price to Earnings (P/E)
- -2.1
- Beta (1Y)
- 0.16
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Switzerland
- Employees
- 10
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
MindMaze Therapeutics Holding SA Business Overview & Revenue Model
Company Description
MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neur...
How the Company Makes Money
RELIEF THERAPEUTICS generates revenue through multiple channels, including the development and licensing of its drug candidates to pharmaceutical companies, which may involve milestone payments and royalties on sales. The company may also engage in s...
MindMaze Therapeutics Holding SA Financial Statement Overview
Summary
Revenue growth and improved gross margin are positives, and leverage is low with a strong equity ratio. However, ongoing net losses, negative EBIT/EBITDA margins, and negative free cash flow keep overall financial strength weak.
Income Statement
35NegativeBalance Sheet
45NeutralCash Flow
30Negative| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.05M | 8.42M | 6.03M | 6.08M | 3.32M | 0 |
| Gross Profit | -1.18M | 5.84M | 4.11M | 4.83M | -8.59M | 0 |
| EBITDA | -18.22M | -16.73M | -108.04M | -50.26M | -32.69M | -6.09M |
| Net Income | -17.04M | -17.12M | -98.18M | -50.79M | -34.70M | -7.83M |
Balance Sheet | ||||||
| Total Assets | 47.99M | 53.22M | 76.39M | 188.80M | 251.62M | 78.05M |
| Cash, Cash Equivalents and Short-Term Investments | 12.50M | 15.08M | 14.56M | 19.24M | 44.76M | 43.15M |
| Total Debt | 1.90M | 2.14M | 2.96M | 4.34M | 4.26M | 891.00K |
| Total Liabilities | 15.35M | 16.56M | 24.16M | 43.38M | 70.09M | 11.00M |
| Stockholders Equity | 32.63M | 36.66M | 52.23M | 145.42M | 181.53M | 67.04M |
Cash Flow | ||||||
| Free Cash Flow | -3.43M | -3.09M | -18.06M | -24.63M | -49.42M | -18.23M |
| Operating Cash Flow | -3.40M | -2.92M | -17.61M | -24.11M | -35.71M | -18.23M |
| Investing Cash Flow | 5.59M | 4.40M | 8.70M | -8.02M | -30.27M | 3.00M |
| Financing Cash Flow | -303.00K | -862.00K | 4.05M | 6.42M | 67.69M | 58.18M |
MindMaze Therapeutics Holding SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MMTX, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.15, and below the 200-day MA of 0.32, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 43.70 is Neutral, neither overbought nor oversold. The STOCH value of 28.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:MMTX.
MindMaze Therapeutics Holding SA Peers Comparison
Overall Rating
CH:BSLN80Outperform
CH:SANN52Neutral
CH:NWRN45Neutral
CH:IDIA41Neutral
CH:MMTX41Neutral
CH:MOLN38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | CHF 885.12M | 16.88 | ― | ― | 4.74% | -28.96% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 52Neutral | CHF 217.91M | -6.24 | 354.99% | ― | 107.08% | 55.54% | |
| 45Neutral | CHF 183.50M | -6.40 | 258.11% | ― | -82.88% | -212.48% | |
| 41Neutral | CHF 1.07B | -3.58 | ― | ― | -5.32% | -95.96% | |
| 41Neutral | CHF 24.80M | -2.13 | -49.18% | ― | ― | ― | |
| 38Underperform | CHF 94.88M | -1.74 | -79.25% | ― | ― | 16.86% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CH:MMTX | MindMaze Therapeutics Holding SA | 0.14 | -2.43 | -94.66% | |
| CH:MOLN | Molecular Partners | 2.35 | -0.88 | -27.13% | |
| CH:BSLN | Basilea Pharmaceutica | 71.90 | 24.15 | 50.58% | |
| CH:IDIA | Idorsia Ltd | 3.97 | 0.73 | 22.34% | |
| CH:NWRN | Newron Pharmaceuticals SpA | 8.64 | -7.28 | -45.73% | |
| CH:SANN | Santhera Pharmaceuticals Holding Ag | 14.22 | 1.92 | 15.61% |
MindMaze Therapeutics Holding SA Corporate Events
MindMaze Sets Global Reimbursement Framework to Scale AI-Powered Neurorehabilitation
MindMaze Therapeutics has detailed a coordinated global reimbursement strategy designed to scale access to its next-generation digital neurorehabilitation therapies and underpin long-term commercial growth. Central to the plan is a U.S. CMS Category...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jan 23, 2026
